SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-23-007302
Filing Date
2023-10-20
Accepted
2023-10-20 13:06:33
Documents
14
Period of Report
2023-10-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT sunshine_8k.htm   iXBRL 8-K 27449
2 AMENDMENT NO. 1 TO WARRANT AGENT AGREEMENT sunshine_1001.htm EX-10.1 6225
  Complete submission text file 0001683168-23-007302.txt   253156

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE sbfm-20231018.xsd EX-101.SCH 3553
4 XBRL DEFINITION FILE sbfm-20231018_def.xml EX-101.DEF 26585
5 XBRL LABEL FILE sbfm-20231018_lab.xml EX-101.LAB 36550
6 XBRL PRESENTATION FILE sbfm-20231018_pre.xml EX-101.PRE 25209
8 EXTRACTED XBRL INSTANCE DOCUMENT sunshine_8k_htm.xml XML 5126
Mailing Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5
Business Address 6500 TRANS-CANADA HIGHWAY 4TH FLOOR POINTE-CLAIRE A8 H9R 0A5 514-426-6161
Sunshine Biopharma, Inc (Filer) CIK: 0001402328 (see all company filings)

IRS No.: 205566275 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41282 | Film No.: 231336679
SIC: 2834 Pharmaceutical Preparations